Lung Cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) Patients with suspected malignant nodules or masses in the lung detected by CT or other imaging examinations should include patients diagnosed with lung cancer, patients with other benign diseases and healthy people, as follows: For lung cancer group, all stages (I, II, III, IV) and pathological types (such as small cell carcinoma, adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, large cell carcinoma, sarcomatoid carcinoma, neuroendocrine carcinoma, etc.) were included as far as possible. Other benign disease groups, such as tuberculosis, pneumonia, lung abscess, pneumoconiosis, intrapulmonary lymph nodes, atelectasis, chronic obstructive pulmonary disease, etc. Healthy people 2) subjects did not receive chemotherapy, radiotherapy or surgery (except for follow-up after lung cancer resection); 3) consider biopsy or surgery for diagnosis or treatment within 60 days; 4) willing to provide breath samples for this clinical study and sign informed consent; 5) The gender and age of the subjects were not limited.
Exclusion criteria
Exclusion criteria: 1) patients with other malignant tumors at the same time or in the past, including but not limited to adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical surgery, ductal carcinoma in situ after radical surgery, and other tumors; 2) previous chemotherapy, targeted therapy or immunotherapy; 3) the pathological results could not be obtained or the pathological results were special pathology such as metastatic cancer; 4) The VOCs related detection results could not be obtained for various reasons; 5) Subjects with unqualified sample quality control; 6) other conditions considered by the investigators as not suitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Exhaled VOCs composition and concentration; | — |
Countries
China
Contacts
Nanjing Drum Tower Hospital